The first ever treatment for secondary progressive MS (SPMS) has been approved by the Therapeutic Goods Administration in Australia. SPMS is a form of MS that can follow on from relapsing remitting MS (RRMS).
Siponimod, marketed under the trade name Mayzent, is an oral treatment in the same class as relapsing remitting medication fingolimod (Gilenya), targeting immune cells.
A parallel submission has also been made to the Pharmaceutical Benefits Advisory Committee (PBAC) for reimbursement under the Pharmaceutical Benefits Scheme (PBS) but has not yet been approved.
For more information please visit MS Australia’s website.